Physician profile
Sankrant Reddy
NPI 1578889564
$4,412.41
in general payments reported to CMS, 2019-2025
29 companies · $977 in 2025
The $977 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $214 · 2021: $212 · 2022: $121 · 2023: $546 · 2024: $1,020 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $785.44 | 2019 | |
| Lundbeck LLC | $546.54 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $449.32 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $340.22 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $240.43 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $237.28 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.08 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $152.91 | 2023-2025 | Auvelity |
| Tris Pharma INC | $138.72 | 2022-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $136.00 | 2024-2025 | Ingrezza |
| Corium, LLC | $106.61 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $102.31 | 2023-2025 | Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $89.96 | 2023-2024 | Jornay Pm |
| Alkermes, INC. | $88.57 | 2022-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $81.04 | 2020-2025 | Adzenys Xr-Odt |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $76.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $75.33 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $74.09 | 2023-2024 | Xelstrym, Secuado |
| Bausch Health US, LLC | $70.43 | 2019-2025 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $62.88 | 2022-2024 | Qelbree |
| Sunovion Pharmaceuticals INC. | $59.42 | 2020-2021 | |
| Almatica Pharma LLC | $53.23 | 2024 | Loreev Xr |
| Livanova USA, INC. | $50.54 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Avanir Pharmaceuticals, INC. | $48.71 | 2019 | |
| Idorsia Pharmaceuticals US INC | $34.48 | 2023-2024 | Quviviq |
| Owp Pharmaceuticals, INC. | $23.07 | 2019 | |
| Adlon Therapeutics L.P. | $19.22 | 2021 | |
| Shire North American Group INC | $18.53 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.05 | 2024 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sankrant Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.